Compare BC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BC | ACAD |
|---|---|---|
| Founded | 1845 | 1993 |
| Country | United States | United States |
| Employees | 14000 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.4B |
| IPO Year | N/A | 2000 |
| Metric | BC | ACAD |
|---|---|---|
| Price | $79.99 | $25.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 22 |
| Target Price | ★ $83.55 | $30.55 |
| AVG Volume (30 Days) | 587.9K | ★ 1.8M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $9.81 | $18.80 |
| Revenue Next Year | $5.11 | $11.70 |
| P/E Ratio | ★ N/A | $1,254.50 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $55.61 | $19.69 |
| 52 Week High | $90.25 | $28.35 |
| Indicator | BC | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 48.10 | 58.95 |
| Support Level | $78.23 | $25.25 |
| Resistance Level | $85.00 | $27.79 |
| Average True Range (ATR) | 2.80 | 0.77 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 47.73 | 29.52 |
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns more than 450 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.